LRRK2
Os inibidores de LRRK2 são compostos que têm como alvo e inibem a atividade da Leucine-Rich Repeat Kinase 2 (LRRK2), uma enzima envolvida em vários processos celulares, incluindo autofagia, tráfego vesicular e inflamação. As mutações no gene LRRK2 estão associadas a um aumento do risco de desenvolver a doença de Parkinson, tornando o LRRK2 um alvo significativo para a pesquisa em doenças neurodegenerativas. Os inibidores de LRRK2 são cruciais para explorar o papel do LRRK2 na doença de Parkinson e para desenvolver potenciais estratégias terapêuticas. Na CymitQuimica, oferecemos uma seleção de inibidores de LRRK2 para apoiar sua pesquisa em neurodegeneração, sinalização de quinase e desenvolvimento terapêutico.
Foram encontrados 42 produtos de "LRRK2"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
BIX 02565
CAS:BIX 02565 is a potent inhibitor of ribosomal S6 kinase 2 (RSK2, IC50: 1.1 nM).Fórmula:C26H30N6O2Pureza:97.44% - 99.7%Cor e Forma:SolidPeso molecular:458.56Ref: TM-T5428
1mg56,00€2mg79,00€5mg118,00€10mg177,00€25mgA consultar50mgA consultar1mL*10mM (DMSO)145,00€MLi-2
CAS:MLi-2: Novel, potent CNS-active LRRK2 inhibitor; IC50s: 0.76nM in vitro, 1.4nM cellular, 3.4nM binding.Fórmula:C21H25N5O2Pureza:98.96%Cor e Forma:SolidPeso molecular:379.46Ref: TM-T16115
1mg58,00€2mg88,00€5mg133,00€10mg188,00€25mg432,00€50mg652,00€100mg929,00€1mL*10mM (DMSO)142,00€RN277
RN277 is an inhibitor of LRRK2 type II kinase (LRRK2type II kinase). It serves as a cellular tool targeting the inactive state of LRRK2. In vitro, RN277 inhibits LRRK1 kinase activity and the kinase activity of LRRK2, with an IC50 of 70 nM. Additionally, it reduces Rab8a phosphorylation in a dose-dependent manner. RN277 is useful for Parkinson's disease research.Cor e Forma:Odour SolidRN341
RN341 is a LRRK2-specific type II kinase inhibitor (IC50 of 296 nM). It prevents the phosphorylation of LRRK2 by stabilizing an open conformation, thereby avoiding S935 dephosphorylation. Additionally, RN341 rescues LRRK2-mediated kinesin motility blockage by preventing microtubule binding. This compound effectively inhibits both wild-type and G2019S LRRK2 at the cellular level, offering a novel avenue for Parkinson's disease research.Cor e Forma:Odour SolidXL01126
XL01126 degrades LRRK2 (DC50: 14 nM G2019S, 32 nM WT), crosses the blood-brain barrier, aiding Parkinson's studies.Fórmula:C50H64ClFN10O6S2Cor e Forma:SolidPeso molecular:1019.69LRRK2 inhibitor 1
CAS:LRRK2 inhibitor 1 is a selective and potent LRRK2 inhibitor with an IC50 of 13 nM.LRRK2 inhibitor 1 inhibits DCLK1 kinase with an IC50 value of 2.61 nM.Fórmula:C20H23N5O4Pureza:99.98%Cor e Forma:SolidPeso molecular:397.43Ref: TM-T11878
1mg74,00€2mg97,00€5mg160,00€10mg264,00€25mg557,00€50mg944,00€100mg1.491,00€1mL*10mM (DMSO)170,00€CZC-54252 hydrochloride
CAS:CZC-54252 hydrochloride: selective LRRK2 inhibitor; IC50 = 1.85/1.28 nM (wild-type/G2019S); neuroprotective; EC50 = 1 nM for G2019S injury.Fórmula:C22H26Cl2N6O4SPureza:98.21%Cor e Forma:SolidPeso molecular:541.45Ref: TM-T39202
5mg52,00€10mg75,00€25mg135,00€50mg215,00€100mg319,00€200mg449,00€1mL*10mM (DMSO)64,00€JH-XII-03-02
CAS:JH-XII-03-02 is a potent and selective leucine-rich repeat kinase 2 (LRRK2) proteolysis targeting chimera (PROTAC) degrader, utilized in Parkinson's Disease (PDFórmula:C43H51N9O10Pureza:98%Cor e Forma:SolidPeso molecular:853.92CC-3240
CAS:CC-3240 (compound 13), a molecular glue degrader of CaMKK2 based on CC-8977, has an IC50 of 9 nM [1].Fórmula:C52H64N6O7SPeso molecular:917.17EB-42486
CAS:EB-42486 is an effective and highly selective inhibitor of G2019S-LRRK2 with an IC50 < 0.2 nM.Fórmula:C22H22N8OPureza:99.53%Cor e Forma:SolidPeso molecular:414.46Ref: TM-T39972
1mg66,00€2mg87,00€5mg147,00€10mg215,00€25mg388,00€50mg577,00€100mg820,00€200mg1.099,00€1mL*10mM (DMSO)161,00€Anti-LRRK2 Antibody (1C773)
Anti-LRRK2 Antibody (1C773) is an antibody targeting LRRK2. Anti-LRRK2 Antibody (1C773) can be used in ELISA, IHC.Cor e Forma:Odour LiquidPF-06447475
CAS:PF-06447475 is a highly effective, specific, brain penetrant LRRK2 inhibitor with IC0 of 3/11 nM for wild type LRRK2 and G2019S LRRK2 respectively.Fórmula:C17H15N5OPureza:98.61% - 99.62%Cor e Forma:SolidPeso molecular:305.33GNE0877
CAS:GNE0877 (GNE 0877) is a highly effective and specific leucine-rich repeat kinase 2 (LRRK2) inhibitor (Ki: 0.7 nM).Fórmula:C14H16F3N7Pureza:98.01% - 99.97%Cor e Forma:SolidPeso molecular:339.32Ref: TM-T6031
1mg44,00€2mg57,00€5mg113,00€10mg177,00€25mg356,00€50mg532,00€100mg760,00€500mg1.558,00€1mL*10mM (DMSO)90,00€LRRK2-IN-1
CAS:LRRK2-IN-1 is an effective and selective LRRK2 inhibitor.Fórmula:C31H38N8O3Pureza:98% - 98.82%Cor e Forma:SolidPeso molecular:570.69PFE-360
CAS:PFE-360 (PF-06685360) is a potent and selective inhibitor of LRRK2 kinase (IC50: 2.3 nM in vivo).
Fórmula:C16H16N6OPureza:98.14% - 99.73%Cor e Forma:SolidPeso molecular:308.34GSK2578215A
CAS:GSK2578215A is a potent and selective LRRK2 kinase inhibitor.Fórmula:C24H18FN3O2Pureza:99.57% - 99.94%Cor e Forma:SolidPeso molecular:399.42GNE-7915 tosylate
CAS:GNE-7915 tosylate is a potent, selective, and brain-penetrant LRRK2 inhibitor, boasting an IC50 value of 9 nM.Fórmula:C26H29F4N5O6SCor e Forma:SolidPeso molecular:615.6PF-06454589
CAS:PF-06454589 is a potent inhibitor of LRRK2.Fórmula:C14H16N6OPureza:99.06%Cor e Forma:SolidPeso molecular:284.32Ref: TM-T7729
2mg34,00€5mg52,00€10mg75,00€25mg128,00€50mg187,00€100mg290,00€200mg419,00€1mL*10mM (DMSO)52,00€HG-10-102-01
CAS:HG-10-102-01 is an inhibitor of leucine-rich repeat kinase 2 (LRRK2, IC50 of 20.3 nM).Fórmula:C17H20ClN5O3Pureza:99.59%Cor e Forma:SolidPeso molecular:377.83Ref: TM-T7196
2mg35,00€5mg55,00€10mg89,00€25mg161,00€50mg250,00€100mg360,00€200mg512,00€1mL*10mM (DMSO)62,00€CZC-25146 hydrochloride
CAS:CZC-25146 is a selective LRRK2 inhibitor with IC50 of 4.76 nM/6.87 nM for wild type LRRK2 and G2019S LRRK2, respectively.
Fórmula:C22H26ClFN6O4SPureza:98.76%Cor e Forma:SolidPeso molecular:525JH-II-127
CAS:JH-II-127 is an oral LRRK2 inhibitor with IC50s: 6.6 nM (WT), 2.2 nM (G2019S), 47.7 nM (A2016T).Fórmula:C19H21ClN6O3Pureza:98.32%Cor e Forma:SolidPeso molecular:416.86Ref: TM-T7155
2mg43,00€5mg66,00€10mg96,00€25mg166,00€50mg259,00€100mg366,00€200mg520,00€1mL*10mM (DMSO)73,00€IKK 16
CAS:IKK 16 (IKK Inhibitor VII) is a selective IκB kinase (IKK) inhibitor for IKK-2, IKK complex and IKK-1 with IC50 of 40 nM, 70 nM and 200 nM, respectively.Fórmula:C28H29N5OSPureza:98.76% - 99.61%Cor e Forma:SolidPeso molecular:483.63Ref: TM-T6176
1mg38,00€2mg50,00€5mg84,00€10mg132,00€25mg233,00€50mg385,00€100mg550,00€200mg782,00€1mL*10mM (DMSO)93,00€CZC-25146
CAS:CZC-25146, a stable LRRK2 inhibitor, IC50: 4.76 nM (wild-type), 6.87 nM (G2019S).Fórmula:C22H25FN6O4SPureza:97.68%Cor e Forma:SolidPeso molecular:488.54GNE-9605
CAS:GNE-9605 is a highly effective, specifical, and brain-penetrant LRRK2 inhibitor (IC50: 19 nM).Fórmula:C17H20ClF4N7OPureza:98.55% - 98.75%Cor e Forma:SolidPeso molecular:449.83GNE-7915
CAS:GNE-7915 is a highly potent, selective and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) inhibitor.Fórmula:C19H21F4N5O3Pureza:98% - ≥95%Cor e Forma:SolidPeso molecular:443.4Ref: TM-T1945
5mg44,00€10mg58,00€25mg108,00€50mg177,00€100mg299,00€200mg389,00€500mg645,00€1mL*10mM (DMSO)48,00€CZC-54252
CAS:CZC-54252 is a potent inhibitor of LRRK2.Fórmula:C22H25ClN6O4SPureza:99.39%Cor e Forma:SolidPeso molecular:504.99PF-06455943
CAS:PF-06455943: LRRK2 inhibitor, IC50=3nM, PET radioligand, used for ADME/neuro PK & Parkinson's research.Fórmula:C17H14FN5OCor e Forma:SolidPeso molecular:323.32LRRK2-IN-10
CAS:LRRK2-IN-10 (compound 34) is a potent, mutation-selective, brain-penetrant inhibitor targeting G2019S-LRRK2 kinase with IC50 values of 11 nM for G2019S-LRRK2Fórmula:C20H15N5OPureza:98%Cor e Forma:SolidPeso molecular:341.37PF-06371900
CAS:PF-06371900 is a potent and highly selective inhibitor of leucine-rich repeat kinase 2 (LRRK2).Fórmula:C17H16N6O2SCor e Forma:SolidPeso molecular:368.41LRRK2-IN-7
CAS:LRRK2-IN-7: potent, selective CNS-active LRRK2 inhibitor, IC50 0.9 nM, >1000x selectivity vs kinases/channels/CYPs.Fórmula:C24H26N6OPureza:99.26%Cor e Forma:SolidPeso molecular:414.5LRRK2-IN-20
CAS:LRRK2-IN-20 (EX. 4.64) is a selective inhibitor of LRRK2 with a potency of pIC50 at 0.7921 nM. This compound is applicable in research studies focused on Parkinson's Disease (PD).Fórmula:C24H32ClN7OCor e Forma:SolidPeso molecular:470.01LRRK2-IN-5
LRRK2-IN-5 is an oral, BBB-penetrating selective inhibitor for LRRK2 with IC50s: 1.2μM (GS) and 16μM (WT); halts LRRK2 autophosphorylation.Fórmula:C24H26F2N4O2SCor e Forma:SolidPeso molecular:472.55LRRK2-IN-12
CAS:LRRK2-IN-12 (compound 1) is a potent inhibitor of LRRK2 (G20195) with an IC 50 of 0.45 nM, LRRK2 WT with an IC 50 of 1.1 nM, and LRRK2 WT ADP-Glo with an IC 50 of 0.46 nM. This compound is utilized in research related to Alzheimer's Disease [1].Fórmula:C18H17ClN8O2Cor e Forma:SolidPeso molecular:412.83LRRK2-IN-3
CAS:LRRK2-IN-3: potent, selective oral LRRK2 blocker, BBB-penetrant, IC50 of 0.6 nM in hPBMCs, for Parkinson's research.Fórmula:C25H29ClF2N6O2Cor e Forma:SolidPeso molecular:518.99LRRK2-IN-13
CAS:LRRK2-IN-13 (Compound 13), with an IC50 value of 0.57 nM, serves as an inhibitor of LRRK2 and exhibits properties that allow it to penetrate the brain [1].Fórmula:C19H19ClN8O2Cor e Forma:SolidPeso molecular:426.86LRRK2-IN-14
CAS:LRRK2-IN-14 (Compound 8), an orally active inhibitor of LRRK2, exhibits an IC 50 of 6.3 nM against LRRK2(G2019S) cell activity and demonstrates inhibitory effects on hERG with an IC 50 of 22 μM. Additionally, LRRK2-IN-14 is permeable to the blood-brain barrier [1].Fórmula:C17H18F3N5O2Cor e Forma:SolidPeso molecular:381.35(R,R)-LRRK2-IN-7
CAS:(R,R)-LRRK2-IN-7 is an isomer of LRRK2-IN-7, a potent and selective LRRK2 kinase inhibitor with CNS penetrance. It exhibits an IC50 of 0.9 nM and demonstrates over 1000-fold selectivity compared to other kinases, ion channels, and CYP enzymes.Fórmula:C24H26N6OPeso molecular:414.50LRRK2-IN-2
CAS:LRRK2-IN-2: selective, potent LRRK2 inhibitor, IC50 of 0.6 nM, oral, crosses blood-brain barrier, for Parkinson's research.Fórmula:C23H23Cl2F3N6O2Cor e Forma:SolidPeso molecular:543.37SRI-31255
CAS:SRI-31255 is an orally active LRRK2 inhibitor, with IC50 values of 520 nM for human wild-type (WT) and 427 nM for the G2019S mutant. It inhibits kinase activity by binding to the ATP-binding pocket of LRRK2, providing neuroprotective effects. SRI-31255 serves as a lead compound for developing LRRK2-targeted therapies for Parkinson’s disease research.Fórmula:C15H14N4Cor e Forma:SolidPeso molecular:250.30LRRK2-IN-16
CAS:LRRK2-IN-16 (compound 25) is an inhibitor of the LRRK2 kinase with an IC50 value of less than 5 μM. It is applicable for research in neurodegenerative and autoimmune diseases.Fórmula:C18H19N5OSCor e Forma:SolidPeso molecular:353.441LRRK2-IN-4
CAS:LRRK2-IN-4: Potent, selective LRRK2 inhibitor, oral, BBB-penetrating, IC50=2.6 nM, potential for Parkinson's.Fórmula:C25H29ClF2N6O2Cor e Forma:SolidPeso molecular:518.99LRRK2-IN-6
LRRK2-IN-6 is an oral, selective LRRK2 inhibitor crossing the blood-brain barrier, targeting GS (IC50: 4.6μM) and WT LRRK2 (IC50: 49μM).Fórmula:C23H24F2N4O2SCor e Forma:SolidPeso molecular:458.52
